Beqaj, S H, Lerner, A M, Fitzgerald, J T · Journal of clinical pathology · 2008 · DOI
This study tested a new blood test method to detect active cytomegalovirus (CMV) infection in ME/CFS patients. The new test, called Copalis, was more sensitive than standard tests at finding signs of active CMV infection, detecting it in about 12% of CMV-exposed patients compared to only 2% with the older method. The researchers suggest this improved test could help identify a subset of ME/CFS patients who have active CMV infection.
Detection of active viral infections in ME/CFS has long been challenging, and better diagnostic tools could help identify which patients might benefit from antiviral approaches and advance understanding of potential infectious triggers. This work demonstrates that assay methodology significantly impacts detection rates and could reshape how clinicians screen for active HCMV in this population. If validated in controlled studies, improved testing could enable more targeted treatment strategies and clarify HCMV's role in disease pathogenesis.
This study does not prove that CMV causes ME/CFS or that active CMV infection is present in all or most ME/CFS patients—only that a subset may have detectable active infection. The cross-sectional design cannot establish causality or temporal relationships, and the study does not compare ME/CFS patients to healthy controls, making it impossible to determine whether active CMV detection is specific to ME/CFS or more general. The findings are from a single clinic and require independent replication before changing clinical practice.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →